BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23790097)

  • 1. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIBF 1120 for the treatment of non-small cell lung cancer.
    Reck M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib for the treatment of non-small-cell lung cancer.
    Rashdan S; Hanna N
    Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
    Noonan S; Man Wong K; Jimeno A
    Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.
    Santos ES; Gomez JE; Raez LE
    Invest New Drugs; 2012 Jun; 30(3):1261-9. PubMed ID: 21350804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
    Roth GJ; Heckel A; Colbatzky F; Handschuh S; Kley J; Lehmann-Lintz T; Lotz R; Tontsch-Grunt U; Walter R; Hilberg F
    J Med Chem; 2009 Jul; 52(14):4466-80. PubMed ID: 19522465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
    Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting VEGF in lung cancer.
    Das M; Wakelee H
    Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motesanib and advanced NSCLC: experiences and expectations.
    Raghav KP; Blumenschein GR
    Expert Opin Investig Drugs; 2011 Jun; 20(6):859-69. PubMed ID: 21534718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
    Wozniak A
    Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
    Bronte G; Passiglia F; Galvano A; Russo A
    Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib: from discovery to the clinic.
    Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
    J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib for the treatment of advanced non-small-cell lung cancer.
    King JW; Lee SM
    Expert Opin Investig Drugs; 2013 Jun; 22(6):765-73. PubMed ID: 23452008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.